Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review

Version 1 : Received: 23 June 2023 / Approved: 26 June 2023 / Online: 26 June 2023 (12:07:15 CEST)

A peer-reviewed article of this Preprint also exists.

Rizzetto, G.; De Simoni, E.; Molinelli, E.; Offidani, A.; Simonetti, O. Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review. Int. J. Mol. Sci. 2023, 24, 12383. Rizzetto, G.; De Simoni, E.; Molinelli, E.; Offidani, A.; Simonetti, O. Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review. Int. J. Mol. Sci. 2023, 24, 12383.

Abstract

Introduction: pembrolizumab showed to increase survival in patients with metastatic melanoma, Con-sidering the numerous oncoming studies, we decided to conduct a narrative review of the latest efficacy evidence regarding the use of pembrolizumab, alone or in combination, in patients with metastatic melanoma. (2) Methods: A search was conducted on Pubmed using "pembrolizumab," and "metastatic melanoma" as keywords, considering studies from 2022 onward. (3) results: we reviewed pembroli-zumab and associations, cost-effectiveness, virus, advanced acral melanoma, long-term outcomes, re-al-life data, biomarkers, obesity, and vaccines (4) Conclusions: pembrolizumab is a fundamental op-tion in the therapy of metastatic melanoma. However, a certain group of patients do not respond and therefore new combination options need to be evaluated. In particular, the use of vaccines tailored to tumor epitopes could represent a breakthrough in the treatment of resistant forms. Further studies with larger sample numbers are needed to confirm preliminary results.

Keywords

advanced melanoma; pembrolizumab; immunotherapy

Subject

Medicine and Pharmacology, Dermatology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.